What is Leerink Partnrs’ Estimate for LXEO FY2025 Earnings?

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) – Analysts at Leerink Partnrs reduced their FY2025 earnings per share estimates for Lexeo Therapeutics in a report released on Monday, March 24th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will post earnings of ($3.18) per share for the year, down from their prior estimate of ($3.00). The consensus estimate for Lexeo Therapeutics’ current full-year earnings is ($3.14) per share. Leerink Partnrs also issued estimates for Lexeo Therapeutics’ FY2026 earnings at ($2.67) EPS and FY2027 earnings at ($2.63) EPS.

Lexeo Therapeutics (NASDAQ:LXEO) last announced its quarterly earnings results on Monday, March 24th. The company reported ($0.78) earnings per share for the quarter, beating the consensus estimate of ($0.87) by $0.09.

LXEO has been the subject of several other research reports. Royal Bank of Canada lowered their target price on shares of Lexeo Therapeutics from $24.00 to $20.00 and set an “outperform” rating for the company in a research note on Tuesday. Leerink Partners lowered their price objective on shares of Lexeo Therapeutics from $19.00 to $18.00 and set an “outperform” rating for the company in a research report on Monday, March 24th. Chardan Capital reissued a “buy” rating and issued a $25.00 target price on shares of Lexeo Therapeutics in a research report on Tuesday. Finally, HC Wainwright restated a “buy” rating and set a $23.00 price target on shares of Lexeo Therapeutics in a research report on Wednesday. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Lexeo Therapeutics has a consensus rating of “Buy” and an average target price of $22.80.

Lexeo Therapeutics Stock Down 0.2 %

Shares of NASDAQ:LXEO opened at $4.10 on Thursday. The company has a market capitalization of $135.57 million, a price-to-earnings ratio of -1.30 and a beta of 3.85. Lexeo Therapeutics has a 12-month low of $2.32 and a 12-month high of $19.50. The business has a 50-day moving average price of $4.05 and a 200 day moving average price of $6.58. The company has a current ratio of 5.95, a quick ratio of 5.95 and a debt-to-equity ratio of 0.01.

Institutional Trading of Lexeo Therapeutics

Large investors have recently made changes to their positions in the company. Frazier Life Sciences Management L.P. purchased a new position in Lexeo Therapeutics in the third quarter worth approximately $11,307,000. Janus Henderson Group PLC raised its holdings in shares of Lexeo Therapeutics by 18.9% in the 3rd quarter. Janus Henderson Group PLC now owns 3,763,195 shares of the company’s stock valued at $33,997,000 after purchasing an additional 599,203 shares in the last quarter. Altium Capital Management LLC purchased a new stake in shares of Lexeo Therapeutics during the 4th quarter worth $2,665,000. Point72 Asset Management L.P. grew its stake in shares of Lexeo Therapeutics by 102.5% during the fourth quarter. Point72 Asset Management L.P. now owns 750,235 shares of the company’s stock worth $4,937,000 after purchasing an additional 379,828 shares in the last quarter. Finally, Verition Fund Management LLC increased its holdings in Lexeo Therapeutics by 84.5% in the third quarter. Verition Fund Management LLC now owns 777,320 shares of the company’s stock valued at $7,027,000 after buying an additional 355,928 shares during the last quarter. 60.67% of the stock is currently owned by hedge funds and other institutional investors.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.